Behavioral Design for Medication Adherence

Why medication adherence is a behavioral challenge

Medication adherence refers to the extent to which people take medicines as agreed with their clinicians: the right dose, at the right time, for the intended duration. Poor adherence is widely recognized in healthcare as a major obstacle to effective treatment, particularly for chronic conditions such as hypertension, diabetes, cardiovascular disease and many mental health conditions. When patients do not take medicines as intended, treatments that work in clinical trials may work far less well in everyday life.

Adherence is not a single decision. It is a chain of behaviors that includes accepting a diagnosis, agreeing to a treatment plan, filling the first prescription, starting the medicine, taking it at the right times, refilling before running out and continuing when symptoms improve or side effects appear. Each link in the chain can break for different reasons. That is why adherence is fundamentally a behavioral design problem, not only a clinical or educational one.

Why people miss doses

Health researchers often distinguish between unintentional and intentional nonadherence. Unintentional nonadherence happens when people mean to take their medicine but forget, run out, become confused by a complex regimen or face practical barriers such as cost, transport or pharmacy access. Intentional nonadherence happens when people decide not to take a medicine as prescribed, often because of side effects, doubts about whether it is necessary, worries about long-term use or a sense that they feel fine without it.

These categories call for different responses. Reminders and simplified regimens may help someone who forgets, but they will not help someone who has concerns about side effects or who does not believe the medicine is needed. Health behavior models, including the health belief model and frameworks grounded in self-determination theory, highlight the role of perceived benefits, perceived barriers, confidence and autonomy. Effective support starts by understanding which barriers apply to which patients.

• Forgetting, especially with multiple daily doses.
• Cost and insurance barriers at the pharmacy.
• Side effects that reduce quality of life.
• Complex regimens involving several medicines at different times.
• Beliefs that the medicine is unnecessary or harmful.
• Limited support from family, clinicians or care teams.

Applying behavioral design principles

The Fogg Behavior Model offers a useful lens: taking a medicine requires motivation, ability and a prompt at the same moment. Ability can be increased by simplifying regimens, synchronizing refills, using blister packs or pill organizers, enabling automatic refills and reducing out-of-pocket cost where possible. Prompts can be improved by anchoring doses to existing routines, such as a morning coffee or evening teeth brushing, and by well-timed reminders that arrive when patients are able to act.

Motivation is best supported through respectful communication rather than pressure. Clear explanations of how a medicine works, what to expect and how to manage side effects help patients make informed choices. Shared decision-making, in which clinicians and patients agree on a plan together, supports autonomy, which self-determination theory identifies as important for sustained behavior change. Habit formation principles also apply: once taking a medicine becomes an automatic part of a daily routine, it depends far less on memory or motivation.

Using data to target the right moments

Adherence data is often fragmented across pharmacy claims, electronic health records, patient apps, call center notes and program enrollment systems. Connecting these sources around the patient journey reveals where adherence typically breaks down. For many conditions, the critical moments are early: whether a first prescription is filled, whether the first refill happens on time, or whether a patient returns after an initial side effect. These are conversion points for adherence.

Behavioral segmentation adds precision. Patients who miss refills by a few days behave differently from those who stop entirely, and those who stop after a side effect differ from those who stop when they feel better. Grouping patients by behavior allows programs to match interventions to needs, such as practical support for some and a conversation with a pharmacist or clinician for others. Predictive KPIs built around these early behaviors give care teams time to help before adherence fails completely.

• Track first fill and first refill timing as early signals.
• Segment patients by adherence pattern, not only by diagnosis.
• Match interventions to the barrier each segment faces.
• Give care teams early alerts while there is still time to help.

Testing and ethical safeguards

Adherence interventions should be tested rather than assumed to work. A reminder message, a refill synchronization program or a pharmacist outreach call may help one population and have little effect on another. Structured pilots and, where appropriate, randomized comparisons between reasonable alternatives show what actually improves behavior. Outcome measures should focus on adherence behaviors and, where possible, on health outcomes, not merely on message opens or program enrollment. Results should also be examined by patient segment, since an average effect can conceal very different responses.

Ethical safeguards are essential in health settings. Every option tested should be acceptable care. Patient data must be protected and used in line with privacy rules and patient expectations. Communication should respect autonomy, recognizing that patients may have legitimate reasons for their choices and that the goal is informed decision-making, not compliance at any cost. Programs should also be checked for equity, ensuring they do not widen gaps between groups with different resources or access.

How Datalidy applies behavioral design to medication adherence

Datalidy's work on medication adherence draws on its roots in clinical and health psychology, behavioral medicine and persuasive technology. In the Observe phase of its Observe, Signal, Design, Test, Scale method, the firm conducts patient and clinician research to understand barriers in context. In the Signal phase, its Behavioral Signals Design methodology connects fragmented health data to identify adherence conversion points, behavioral types and predictive KPIs that give care teams earlier signals.

In the Design phase, the firm develops patient engagement strategies, digital health features, health communication and care team workflows that address specific barriers. The Test phase validates them through pilots and appropriate experiments, and the Scale phase supports implementation through dashboards and team coaching. Datalidy works with health systems, digital health companies and health-related organizations, always guided by the principle that behavioral science should help patients do what they already want to do for their own health.

Frequently asked questions